VEGFR-3


Also found in: Medical.
AcronymDefinition
VEGFR-3vascular endothelial growth factor C/D receptor
References in periodicals archive ?
An indirect ELISA was performed to detect the presence of VEGFR-3 specific autoantibodies in rat sera from control, sham, and BDL groups.
However, the VEGFR-1, VEGFR-2, and VEGFR-3 expression were not significantly correlated with VHL mutation.
1 July 2014 - A study, conducted by German researchers and published today in the journal BMC Cancer, has indicated that VEGFR-3 and CXCR4 are predictive biomarkers for treatment with oxaliplatin/leucovorin/5-FU (FLO) or cisplatin/leucovorin/5-FU (FLP) in patients with advanced oesophagogastric cancer.
In addition, to clarify the mechanisms of antitumor and antimetastatic actions through lymph nodes, we examined the effects of wogonin on VEGFR-3 expression and VEGF-C-induced the phosphorylation of VEGFR-3 in lymphatic endothelial cells, on VEGF-C and hypoxia inducible factor (HIF-l[alpha]) expression in LM8 cells, and on cyclooxygenase (COX)-2 and cytokine production in macrophages.
Importantly, the authors showed that combined use of antibodies blocking growth factor binding VEGFR-3 dimerization provided not only an additive, but also a synergistic inhibition.
inhibits FLT-3, KIT, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-[alpha], PDGFR-[beta], CSF1-R, RET
Similarly, by inhibiting the tyrosine kinase domains of VEGFR-1, VEGFR-2, and VEGFR-3 and other receptors (Raf, PDGFR-B, KIT, FLT-3, and RET), the oral drug Nexavar (Bayer) may compare favourably to antibodies targeting VEGF / VEGFR signalling.
The key, indicate the researchers, is the unexpected presence of large amounts of the protein VEGFR-3 (vascular endothelial growth factor receptor-3) on the top epithelial layer of normal healthy corneas.
ImClone Systems is currently developing an antibody-based drug targeting VEGFR-3 for the treatment of solid tumours.
Nexavar (sorafenib) was shown to inhibit multiple intracellular (C-RAF, B-RAF and mutant B-RAF) and cell surface kinases (KIT, FLT-3, RET, VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-U).
Specific targets include insulin-like growth factor-1 receptor (IGF-1R), vascular endothelial growth factor receptor-1 (VEGFR-1), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor alpha (PDGFRa), FMS-like tyrosine kinase 3 receptor (FLT3), fibroblast growth factor receptor 3 (FGFR3), among others.
Specific targets include insulin-like growth factor-1 receptor (IGF-1R), vascular endothelial growth factor receptor-1 (VEGFR-1), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor alpha (PDGFR[eth]), FMS-like tyrosine kinase 3 receptor (FLT3), fibroblast growth factor receptor 3 (FGFR3), among others.